首页期刊导航|Journal of Veterinary Pharmacology and Therapeutics
期刊信息/Journal information
Journal of Veterinary Pharmacology and Therapeutics
Blackwell Scientific Publications
Journal of Veterinary Pharmacology and Therapeutics

Blackwell Scientific Publications

0140-7783

Journal of Veterinary Pharmacology and Therapeutics/Journal Journal of Veterinary Pharmacology and TherapeuticsSCIISTP
正式出版
收录年代

    Application of pharmacokinetic/pharmacodynamic concepts to the development of treatment regimens for sporadic canine urinary tract infections: Challenges and paths forward

    Ron A. MillerTomás Martín‐JiménezMichele J. SharkeyMarilyn N. Martinez...
    11页
    查看更多>>摘要:Abstract Antimicrobial efficacy can be predicted based on infection site exposure to the antimicrobial agent relative to the in vitro susceptibility of the pathogen to that agent. When infections occur in soft tissues (e.g., muscle, blood, and ligaments), exposure at the infection site is generally assumed to reflect an equilibrium between the unbound concentrations in plasma and that in the interstitial fluids. In contrast, for sporadic urinary tract infections (UTIs) in dogs and uncomplicated UTIs in humans, the primary site of infection is the bladder wall. Infection develops when bacteria invade the host bladder urothelium (specifically, the umbrella cells that form the urine‐contacting layer of the stratified uroepithelium) within which these bacteria can avoid exposure to host defenses and antimicrobial agents. Traditionally, pathogen susceptibility has been estimated using standardized in vitro tests that measure the minimal concentration that will inhibit pathogen growth (MIC). When using exposure–response relationships during drug development to explore dose optimization, these relationships can either be based upon an assessment of a correlation between clinical outcome, drug exposure at the infection site, and pathogen MIC, or upon benchmark exposure‐response relationships (i.e., pharmacokinetic/pharmacodynamic indices) typically used for the various drug classes. When using the latter approach, it is essential that the unbound concentrations at the infection site be considered relative to the MIC within the biological matrix to which the pathogen will be exposed. For soft tissue infections, this typically is the unbound plasma concentrations versus MICs determined in standardized media such as cation‐adjusted Mueller Hinton broth, which is how many indices were originally established. However, for UTIs, it is the unbound drug concentrations within the urine versus the MICs in the actual urine biophase that needs to be considered. The importance of these relationships and how they are influenced by drug resistance, resilience, and inoculum are discussed in this review using fluoroquinolones and beta‐lactams as examples.

    Can diarrhea affect the pharmacokinetics of racecadotril in neonatal calves?

    Bunyamin TrasMahmut OkTugba Melike ParlakMerve Ider...
    6页
    查看更多>>摘要:Abstract This study was aimed to determine the pharmacokinetics of antisecretory‐acting racecadotril, used in the treatment of diarrhea in humans and dogs, following oral administration in both neonatal calves with healthy and neonatal calves with infectious diarrhea. The study was carried out on a total of 24 Holstein calves (2–20?days), of which 6 were healthy and 18 were infectious diarrhea. Calves with infectious diarrhea were divided into 3 groups according to the infectious agent (Escherichia coli, Cryptosporidium parvum, and rotavirus/coronavirus). Racecadotril was administered orally at 2.5?mg/kg dose to calves. The plasma concentrations of racecadotril and its main active metabolite (thiorphan) were determined using HPLC‐UV. The pharmacokinetic parameters were analyzed using the non‐compartmental method. In healthy calves, the t1/2?z, Cmax, Tmax, and AUC0‐12 of racecadotril were determined 4.70?h, 377?ng/ml, 0.75?h, and 1674?h?×?ng/ml, respectively. In the plasma of calves with infectious diarrhea, racecadotril and thiorphan were only detected at the sampling time from 0.25 to 1.5?h. As in calves with infectious diarrhea, thiorphan in plasma was only detected in healthy calves from 0.25 to 1.5?h. Racecadotril showed a large distribution volume, rapid elimination, and low metabolism to thiorphan in healthy calves.

    A validated UPLC‐MS/MS method for quantification of glutamine in plasma and pharmacokinetic study of oral glutamine tablets in healthy Beagles

    Dongying LiuFanxi GuoYuanqian YuYuqing Zhou...
    8页
    查看更多>>摘要:Abstract This study aimed to clarify the laws of glutamine tablets absorption, distribution, and metabolism in Beagles and to provide a basis for formulating dosing regimens. Twelve healthy Beagles were enrolled the absolute bioavailability study with a crossover design . Glutamine tablets (240?mg/kg b.w.) or glutamine sterile solution (60?mg/kg b.w.) were administered. A method for the determination of glutamine in Beagles' plasma by UPLC‐MS/MS was established, with high sensitivity, specificity, and simplicity. Based on the study of endogenous glutamine concentration, the mean concentration of the four time points before drug administration was selected as the background concentration of glutamine. Pharmacokinetic parameters were calculated by non‐compartment model. The Cmax of glutamine was 136.11?±?72.51?μg/ml, Tmax was 0.85?±?0.29?h, and t1/2λz was 0.42?±?0.27?h after oral administration. The AUC0?t of glutamine was 116.30?±?75.15?h·μg/ml vs. 44.55?±?22.48?h·μg/ml following oral and IV administration, respectively, with an absolute bioavailability of 64.74%?±?19.18%. The results showed glutamine was quickly absorbed and eliminated in Beagles with high bioavailability. Therefore, glutamine is suitable to be prepared as oral tablets and recommended to shorten the dosing interval.

    Pseudomonas aeruginosa susceptibility, antibiogram and clinical interpretation, and antimicrobial prescribing behaviors for dogs with otitis in the Midwestern United States

    Kate S. KuKanichMary Bagladi‐SwansonButch KuKanich
    10页
    查看更多>>摘要:Abstract Pseudomonas aeruginosa (P.?aeruginosa) can cause otitis in dogs that is nonresponsive to empirical therapy. This study evaluated P.?aeruginosa isolates (N?=?216) from canine ear swabs submitted to the Kansas State Veterinary Diagnostic Laboratory from 2018–2020 to create an antibiogram and minimum inhibitory concentration distributions using Clinical Laboratory Standards Institutes breakpoints. Multidrug resistance was defined as non‐susceptibility to ≥1 drug from ≥3 antimicrobial classes. Submitting veterinarians (N?=?83) were invited to complete a survey about antimicrobial use and otitis management. Susceptibility was higher for aminoglycosides [gentamicin (82%, 177/216) and amikacin (81%, 175/216)] than fluoroquinolones [marbofloxacin (67%, 145/216), enrofloxacin (32%, 70/216), and orbifloxacin (18%, 39/216)]. Most responding veterinarians (54%, 15/28) prescribe topical aminoglycosides as first‐line therapy for canine otitis, but 71% (15/21) prescribe fluoroquinolones if rods are seen cytologically. Ceftazidime, imipenem, and piperacillin‐tazobactam showed high susceptibility and are used rarely. Multidrug resistance was present in 13% (28/216) of isolates. Based on in vitro susceptibility, topical aminoglycosides might be more effective than fluoroquinolones for P.?aeruginosa otitis, but efficacy studies are required. Susceptibility testing is encouraged for cases not responding to empirical therapy but has limitations because topical preparations have high concentrations and otic breakpoints are not available.

    Pharmacokinetic/pharmacodynamic modeling of ketoprofen and flunixin at piglet castration and tail‐docking

    Emma NixonJason T. ChittendenRonald E. BaynesKristen M. Messenger...
    17页
    查看更多>>摘要:Abstract This study performed population‐pharmacokinetic/pharmacodynamic (pop‐PK/PD) modeling of ketoprofen and flunixin in piglets undergoing routine castration and tail‐docking, utilizing previously published data. Six‐day‐old male piglets (8/group) received either ketoprofen (3.0?mg/kg) or flunixin (2.2?mg/kg) intramuscularly. Two hours post‐dose, piglets were castrated and tail docked. Inhibitory indirect response models were developed utilizing plasma cortisol or interstitial fluid prostaglandin E2 (PGE2) concentration data. Plasma IC50 for ketoprofen utilizing PGE2 as a biomarker was 1.2?μg/ml, and ED50 for was 5.83?mg/kg. The ED50 calculated using cortisol was 4.36?mg/kg; however, the IC50 was high, at 2.56?μg/ml. A large degree of inter‐individual variability (124.08%) was also associated with the cortisol IC50 following ketoprofen administration. IC50 for flunixin utilizing cortisol as a biomarker was 0.06?μg/ml, and ED50 was 0.51?mg/kg. The results show that the currently marketed doses of ketoprofen (3.0?mg/kg) and flunixin (2.2?mg/kg) correspond to drug responses of 33.97% (ketoprofen‐PGE2), 40.75% (ketoprofen‐cortisol), and 81.05% (flunixin‐cortisol) of the maximal possible responses. Given this information, flunixin may be the best NSAID to use in mitigating castration and tail‐docking pain at the current label dose.

    Pharmacokinetics of grapiprant and effects on TNF‐alpha concentrations following oral administration to horses

    Silke L. HoffmannKelsey SeminoffDaniel S. McKemiePhilip H. Kass...
    6页
    查看更多>>摘要:Abstract Grapiprant is a prostaglandin E2 receptor antagonist that has been found to be an effective anti‐inflammatory in dogs and that is devoid of some of the adverse effects associated with traditional NSAIDs that elicit their effects through inhibition of PGE2 production. Previously published reports have described the pharmacokinetics of this drug in horses when administered at 2?mg/kg; however, pharmacodynamic effects in this species have yet to be described. The objective of the current study was to describe the pharmacokinetics and pharmacodynamics of grapiprant at a higher dose. Eight horses received a single oral administration of 15?mg/kg. Plasma concentrations were determined for 96?h using liquid chromatography–tandem mass spectrometry. Non‐compartmental analysis was used to determine pharmacokinetic parameters. Pharmacodynamic effects were assessed ex vivo by stimulating blood samples with PGE2 and determining TNF‐ɑ concentrations. Maximum concentration, time to maximum concentration and area under the curve were 327.5 (188.4–663.0) ng/ml, 1 (0.75–2.0) hour and 831.8 (512.6–1421.6) h*ng/ml, respectively. The terminal half‐life was 11.1 (8.27–21.2) hr. Significant stimulation of TNF alpha was noted for 2–4?h post‐drug administration. Results of this study suggest a short duration of EP4 receptor engagement when administered at a dose of 15?mg/kg.

    Control of ticks on horses using abamectin‐impregnated ear tags. A pharmacokinetic and pharmacodynamic study

    Arno WernersInga KarasekCatherine ButlerJames Yeatts...
    8页
    查看更多>>摘要:Abstract Several different tick species are known to infest horses. Aside from causing serious health and welfare issues, including anaemia, ill thrift, and immunosuppression, ticks can transmit a variety of important, sometimes zoonotic, pathogens. The successful prevention and treatment of tick infestations have been described, but the information is scarce and, in many instances, anecdotal. Here we describe a practical and affordable prevention of tick infestation by using abamectin‐impregnated cattle ear tags affixed to a safety collar. We have assessed the radial distribution of abamectin by analyzing hair samples, as well as its efficacy against tick infestations. The study results show that abamectin distributes across horse skin from the site of application and its associated effectiveness in reducing the tick burden.

    Pharmacokinetics of carprofen following single and repeated intravenous administrations of different doses in sheep

    Orhan CorumDevran CoskunDuygu Durna CorumMerve Ider...
    7页
    查看更多>>摘要:Abstract The aim of this study was to determine the pharmacokinetics of carprofen following single and repeated intravenous (IV) administrations at 1.4 and 4?mg/kg doses in sheep. The study was carried out on twelve sheep in two experiments as single‐ and multiple‐dose pharmacokinetics. In experiment 1, carprofen was administered via IV at single doses of 1.4 (n?=?6) and 4?mg/kg (n?=?6) in a randomized parallel design. In experiment 2, the same dose groups in experiment 1 following the 21‐day washout period received intravenously carprofen every 24?h for 5?days. Plasma concentrations were measured using high‐performance liquid chromatography–UV and analyzed by a two‐compartment open model. After the single administration of 1.4?mg/kg dose, the t1/2α, t1/2el, MRT, ClT, Vdss, and AUC were 0.62?h, 27.57?h, 38.78?h, 2.72?ml/h/kg, 105.26?ml/kg, and 515.12?h*μg/ml, respectively. Carprofen at a single dose of 4?mg/kg showed prolonged t1/2el and MRT, and increased Vdss. On day 5 after the repeated administration of the 1.4?mg/kg dose, the t1/2α, t1/2el, MRT, ClT, Vdss, and AUC were 1.12?h, 57.48?h, 82.18?h, 0.55?ml/h/kg, 45.43?ml/kg, and 2532?h*μg/ml, respectively. Carprofen at a repeated dose of 4?mg/kg showed increased ClT and Vdss and decreased AUC/dose. Although the long t1/2?z in single and multiple IV dose studies suggest the possibility of its effective use, the IV route may not be practical in sheep. Therefore, oral and subcutaneous routes of carprofen in sheep would be more valuable in clinical settings.

    Pharmacokinetics of meloxicam in laying hens after single intravenous, oral, and intramuscular administration

    Hao‐Tian ShaoFang YangJun‐Cheng ChenMei Zhang...
    7页
    查看更多>>摘要:Abstract The objective of this study was to determine the pharmacokinetics of meloxicam after a single intravenous (IV), intramuscular (IM), and oral (PO) dose at 1?mg/kg body weight in Jing Hong laying hens. Blood samples were collected at predetermined time points. Plasma meloxicam concentrations were determined using a validated high‐performance liquid chromatography (HPLC) assay method and then subjected to a non‐compartmental analysis. After IV administration, meloxicam had a mean (±SD) volume of distribution at steady‐state (Vdss) of 206.50?±?25.23?ml/kg, a terminal half‐life (t1/2λ) of 5.45?±?0.53?h, and a total body clearance (Cl) of 26.48?±?4.13?ml/h/kg. After PO and IM administration, meloxicam was absorbed relatively rapidly: the peak concentrations (Cmaxs) of 3.04?±?0.56 and 8.94?±?2.31?μg/ml were observed at 3.08 and 0.80?h, respectively. After PO and IM administration, the absolute bioavailability (F) was determined as 70.13% and 125.50%, respectively. Assuming that hens shared the same analgesic threshold of meloxicam (0.5?μg/ml) with humans, the plasma concentrations after three different routes (PO, IM, and IV) of administration were above this value for 16.7, 19.2, and 14.9?h, respectively.

    Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration

    Alissa B. MonesOlivia A. PetritzHeather K. KnychMiranda J. Sadar...
    6页
    查看更多>>摘要:Abstract Maropitant citrate is a synthetic neurokinin‐1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmacokinetic profile of a single dose of maropitant citrate 1 and 2?mg/kg subcutaneously (SC) in eight Rhode Island Red hens (Gallus gallus domesticus). A crossover study design was used with 1‐week washout between trials. Blood samples were collected over 36?h after drug administration. Plasma concentrations were measured using liquid chromatography–tandem mass spectrometry and pharmacokinetic parameters were determined via non‐compartmental analysis. The mean maximum plasma concentration, time to maximum concentration, and elimination half‐life following 1 and 2?mg/kg SC were 915.6?±?312.8?ng/ml and 1195.2?±?320.2?ng/ml, 0.49?±?0.21?h and 1.6?±?2.6?h, and 8.47?±?2.24?h and 8.58?±?2.6?h, respectively. Pharmacokinetic data suggests doses of 1 or 2?mg/kg SC may be administered every 12–24?h to maintain above target plasma concentration similar to dogs (90?ng/ml). These data provide a basis for further investigation of maropitant citrate pharmacokinetics and pharmacodynamics in birds.